BPI-371153, an orally bioavailable small molecule PD-L1 inhibitor

被引：0

作者：

Wang, Yiqian ^{[1
]}

Jing, Xiangyan ^{[1
]}

Chen, Hong ^{[1
]}

Zhang, Huijuan ^{[1
]}

Ma, Tianyi ^{[1
]}

Zhang, Yao ^{[1
]}

Zhang, Chunhui ^{[1
]}

Zhang, Guangzhi ^{[1
]}

Liu, Xiangyong ^{[1
]}

Yan, Dan ^{[1
]}

Guo, Jing ^{[1
]}

Lan, Hong ^{[1
]}

Wang, Jiabing ^{[1
]}

Ding, Lieming ^{[2
]}

机构：

[1] Betta Pharmaceut Co LTD, Beijing, Peoples R China

[2] Betta Pharmaceut Co LTD, Hangzhou, Peoples R China

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5444

引用

页数：2

共 50 条

[1] A first-in-human, phase I study of BPI-371153, a novel small-molecule PD-L1 inhibitor, in advanced solid tumors or recurrent/refractory (r/r) lymphoma
Yang, J.
Yu, Y.
Ren, X.
Zhong, D.
Sun, M.
Wen, Q.
Du, X.
Liu, X.
Shen, Z.
Li, P.
Ding, L.
Shi, Y-K.
ANNALS OF ONCOLOGY, 2024, 35 : S1427 - S1427
[2] Design, synthesis, and optimization of novel PD-L1 inhibitors and the identification of a highly potent and orally bioavailable PD-L1 inhibitor
Ruengsatra, Tanachote
Soponpong, Jakapun
Nalinratana, Nonthaneth
Jirapongwattana, Niphat
Dunkoksung, Wilasinee
Rattanangkool, Eakkaphon
Deesiri, Sirikan
Srisa, Jakkrit
Songthammanuphap, Songkiat
Udomnilobol, Udomsak
Prueksaritanont, Thomayant
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 277
[3] CCX559, an orally administered small molecule PD-L1 inhibitor for the treatment of solid tumors
Sullivan, Kathleen M.
Miao, Shichang
Yue, Huibin
Zhao, Niky
Li, Chris
Tai, Ezra
Ebsworth, Karen
Rico, Gonzalo Tapia
De Souza, Paul
Schall, Tom
Zhang, Penglie
CANCER RESEARCH, 2022, 82 (12)
[4] BPI-472372: a potent and orally bioavailable small molecule inhibitor of CD73 for cancer immunotherapy
Han, Han
Yang, Xiaofeng
Zhao, Ying
Wang, Jin
Yang, Xiang
Ju, Xuepeng
Zhao, Jiayu
Zou, Zhengyao
Chen, Haibo
Liu, Xiaoyun
Guo, Jing
Yang, Cheng
Lan, Hong
Wu, Hao
Ding, Lieming
Wang, Jiabing
CANCER RESEARCH, 2023, 83 (07)
[5] Novel Small-Molecule PD-L1 Inhibitor Induces PD-L1 Internalization and Optimizes the Immune Microenvironment
Sun, Chengliang
Yin, Mingxiao
Cheng, Yao
Kuang, Zean
Liu, Xiaojia
Wang, Gefei
Wang, Xiao
Yuan, Kai
Min, Wenjian
Dong, Jingwen
Hou, Yi
Hu, Lingrong
Zhang, Guoyu
Pei, Wenli
Wang, Liping
Sun, Yanze
Yu, Xinmiao
Xiao, Yibei
Deng, Hongbin
Yang, Peng
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (03) : 2064 - 2083
[6] In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
Lu, Chih-Hao
Chung, Wei-Min
Tsai, Chun-Hao
Cheng, Ju-Chien
Hsu, Kai-Cheng
Tzeng, Huey-En
SCIENTIFIC REPORTS, 2022, 12 (01)
[7] In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
Chih-Hao Lu
Wei-Min Chung
Chun-Hao Tsai
Ju-Chien Cheng
Kai-Cheng Hsu
Huey-En Tzeng
Scientific Reports, 12
[8] Small molecule PD-L1 inhibitor modulates expression of PD-L1 on the cell surface - a potential mechanism of blocking interaction with PD-1
Weitsman, G.
Chan, J. Nuo En
Nedbal, J.
Barber, P. R.
Volgina, A.
Stevens, C.
Poland, S.
Ameer-Beg, S.
Suhling, K.
Rios-Doria, J.
Ng, T.
EUROPEAN JOURNAL OF CANCER, 2022, 174 : S70 - S70
[9] Discovery and characterization of a novel small molecule brain penetrant PD-L1 inhibitor
Zhang, Yongxian
Zhang, Mingming
Zhao, Baowei
Yu, Hongping
Xu, Yao-Chang
Chen, Zhui
Ying, Haiyan
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[10] CA-170-A Potent Small-Molecule PD-L1 Inhibitor or Not?
Musielak, Bogdan
Kocik, Justyna
Skalniak, Lukasz
Magiera-Mularz, Katarzyna
Sala, Dominik
Czub, Miroslawa
Stec, Malgorzata
Siedlar, Maciej
Holak, Tad A.
Plewka, Jacek
MOLECULES, 2019, 24 (15):

← 1 2 3 4 5 →